Organic Process Research & Development 2004, 8, 22−27
Efficient Preparation of a Key Intermediate in the Synthesis of Roxifiban by
Enzymatic Dynamic Kinetic Resolution on Large Scale¶
Jaan A. Pesti,* Jinguao Yin,† Lin-hua Zhang,‡ Luigi Anzalone,| Robert E. Waltermire, Philip Ma, Edward Gorko,
Pat N. Confalone,∇ Joseph Fortunak, Charlotte Silverman,O John Blackwell,# J. C. Chung,§ Michael D. Hrytsak,
Mary Cooke, Lakisha Powell, and Charles Ray
Process Research and DeVelopment, Bristol-Myers Squibb Pharmaceutical Research Institute, PO Box 4000,
Princeton, New Jersey 08543-4000, U.S.A.
Abstract:
and dampen the typical peak/valley pharmacokinetic profile
seen for other therapies. This property, among others,
encouraged us to develop a safe, efficient, and inexpensive
large-scale process to prepare roxifiban to advance it into
the clinic.2,3 Herein we describe the development of a
practical process for the preparation of the key intermediate
2, including the transition from a kinetic to a dynamic kinetic
resolution and the scale-up of this chemistry in the pilot
plant.4
Additional information is presented for the transformation of
a kinetic resolution into a dynamic kinetic resolution of the
isobutyl ester 5b to form the acid 2 in high yield and ee via the
intermediacy of a thioester 6c, (Pesti, J. A.; Yin, J.; Zhang, L.-
H; Anzalone, L. J. Am. Chem. Soc. 2001, 123, 11075-11076.).
The development of optimized reaction conditions for the
preparation of 6c, its dynamic kinetic resolution to 2, and the
scale-up of both reactions into a pilot plant are described.
Recent reports have identified roxifiban (1) as a potent
and selective antagonist of the platelet glycoprotein IIb/IIIa
receptor.1 This isoxazoline derivative holds strong promise
for the prevention and treatment of a wide variety of
thrombotic diseases resulting from undesired platelet adhe-
sion such as stroke, acute myocardial infarction, transient
ischemic attack, and unstable angina. The efficacy of existing
anti-platelet therapies is well established. However, none
possesses all of the key attributes desired by clinicians,
namely selectivity for the platelet, freedom from adverse
effects, activity versus all agonists, rapid onset of action,
and oral activity. The ability of roxifiban to bind to both
activated and resting platelets is unlike other known IIb/IIIa
antagonists. This reservoir of 1 residing on unactivated
platelets is expected to result in increased anti-platelet activity
Results and Discussion
Background. The chiral acid 2 has been previously
resolved by chiral preparative HPLC, by fractional crystal-
lization of its cinchonidine salts,5 or via an enzyme-mediated
kinetic resolution of 5a, itself prepared by a highly efficient
[3 + 2] cycloaddition (Scheme 1).1 As the n-butyl butenoate
4a was not readily available, we found a better alternative
to be the isobutyl ester 4b which is inexpensive and available
in large quantities. This reaction regiospecifically produced
5b and was smoothly scaled up in the pilot plant.2,3
Fortuitously, the conditions previously established for
enzymatic resolution of the n-butyl ester 5a were also
effective for the i-butyl ester 5b.2,3,5 The R-enantiomer was
selectively hydrolyzed, isolated, and purified after separation
from the remaining S-ester by simple filtration, eventually
on large scale in our pilot plant. The unreacted S-isomer was
subsequently racemized and returned for another cycle of
¶ This work was conducted while the authors were part of the DuPont
Pharmaceutical Company and its predecessor, the DuPont Merck Pharmaceutical
Company.
* To whom correspondence should be addressed. Telephone: (609) 252-3703.
† Current address: Schering-Plough Research Institute, Chemical Process
Research & Development, 1011 Morris Ave., U-13-2000 Union, NJ 07083.
‡ Current address: Gilead Sciences, Inc., 333 Lakeside Drive, Foster City,
CA 94404.
| Current address: Johnson & Johnson, Pharmaceutical Research & Develop-
ment, L.L.C., Welsh and McKean Roads, Spring House, PA 19477.
3 Current address: EI duPont de Nemours and Company, Dupont Agricultural
Products, Stine/Haskell Laboratories, Newark, DE 19714.
Current address: Abbott Labs, Global Process R&D, 1401 Sheridan Road,
North Chicago, IL 60064-6291.
O Current address: Analytical Development, AstraZeneca Pharmaceuticals,
NLW2, 1800 Concord Pike, Wilmington, DE 19850-5437.
# Current address: Rhodia Pharma Solutions, 383 Phoenixville Pike, Malvern,
PA 19355.
§ Current address: Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury
Road, Ridgefield, CT 06877.
(2) Zhang, L.-h; Chung, J. C.; Costello, T. D.; Valvis, I.; Ma, P.; Kauffman,
G. S.; Ward, R. J. Org. Chem. 1997, 62, 2466-2470.
(1) (a) Xue, C.-B.; Mousa, S. A. Drugs Future 1998, 23, 707-711. (b) Xue,
C.-B.; Wityak, J.; Sielecki, T. M.; Pinto, D. J.; Batt, D. G.; Cain, G. A.;
Sworin, M.; Rockwell, A. L.; Rodercik, J. J.; Wang, S.; Orwat, M. J.; Frietze,
W. E.; Bostrom, L. L.; Liu, J.; Higley, C. A.; Rankin, F. W.; Tobin, A. E.;
Emmett, G.; Lalka, G. K.; Sze, J. Y.; Di Meo, S. V.; Mousa, S. A.; Thoolen,
M. J.; Racanelli, A. L.; Hausner, E. A.; Reilly, T. M.; DeGrado, W. F.;
Wexler, R. R.; Olson, R. E. J. Med. Chem. 1997, 40, 2064-2084.
(3) Zhang, L.-h; Anzalone, L.; Ma, P.; Kauffman, G. S.; Storace, L.; Ward, R.
Tetrahedron Lett. 1996, 37, 4455-4458.
(4) Parts of this work have been previously published: Pesti, J. A.; Yin, J.;
Zhang, L.-h; Anzalone, L. J. Am. Chem. Soc. 2001, 123, 11075-11076.
(5) Wityak, J.; Sielecki, T. M.; Pinto, D. J.; Emmett, G.; Sze, J. Y.; Liu, J.;
Tobin, E.; Wang, S.; Jiang, B.; Ma, P.; Mousa, S. A.; Wexler, R. A.; Olson,
R. E. J. Med. Chem. 1997, 40, 50-60.
22
•
Vol. 8, No. 1, 2004 / Organic Process Research & Development
10.1021/op0300239 CCC: $27.50 © 2004 American Chemical Society
Published on Web 12/24/2003